📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄

About this document — a plain-language guide

What it is. Module 3.2.A appendices (e.g., facilities, adventitious-agent safety) and 3.2.R regional quality information.

Why it exists. Some quality information is either supplementary (appendices, such as viral/TSE safety) or region-specific. This section holds those elements so the core S and P sections stay clean.

How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.

Format & governing standard. ICH M4Q §3.2.A / §3.2.R · Q5A(R2) · Q7

Module 3.2.A Appendices & 3.2.R Regional Information — GLPI-103

Field	Value
Document ID	M3-AR
Version	2.0 (expanded)
Standard	ICH M4Q §3.2.A / §3.2.R · Q5A(R2) · Q7
Confidentiality	Confidential

[MOCK — deep-knowledge assumption] Appendices and regional quality information for the GLPI-103 drug substance and products.

Change History

Version	Date	Author	Summary
1.0	2026-06-29	CMC / Reg-CMC	Initial
2.0	2026-06-30	CMC / Reg-CMC	Expanded — facilities, adventitious agents, SNAC novel-excipient qualification, regional content

3.2.A.1 Facilities & Equipment

Named GMP facilities perform (i) drug-substance solid-phase synthesis, preparative-HPLC purification and lyophilisation; (ii) aseptic fill-finish of the IV product (Grade A/B cleanrooms, validated isolator/RABS); and (iii) solid-dose manufacture (direct compression) of the oral tablet. Utilities (WFI, clean steam, HVAC) and equipment are qualified (IQ/OQ/PQ); uni-directional product/personnel flow and segregation prevent cross-contamination; a multi-product matrix with cleaning-validation (carry-over limits) is in place.

3.2.A.2 Adventitious Agents Safety Evaluation (Q5A(R2))

GLPI-103 is a chemically synthesised peptide of non-biological origin, minimising viral/TSE risk; no animal-derived raw materials are used in synthesis (vegetable-origin or synthetic reagents; TSE/BSE-free declarations on file for any ruminant-contact material). Microbial control is assured by bioburden and bacterial-endotoxin limits on the drug substance and by the sterilising-grade filtration and aseptic process for the IV product.

3.2.A.3 Novel Excipients — SNAC (oral permeation enhancer)

The oral product contains sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) as a functional permeation enhancer. Although SNAC has regulatory precedent (oral semaglutide), it is controlled here to a full internal specification (identity, assay, related substances, residual solvents, heavy metals) with its own characterisation and non-clinical safety qualification (the toxicology program qualified the SNAC level used; M4-2.3 §6); stability of SNAC within the tablet is covered by the drug-product stability programme (M3-STAB).

3.2.R Regional Information

Region	Regional quality content
FDA (US)	Executed/representative batch records; method-validation packages; comparability protocols; Certificates of Analysis; container-closure & device (pen) information
EMA (EU)	Qualified Person (QP) declaration; process-validation scheme; site GMP certificates; TSE compliance (EDQM); novel-excipient (SNAC) regional dossier
MFDS (KR)	Korean GMP (KGMP) documentation; local DMF/registration for the active and SNAC; import testing/local release as required

3.3 Literature References

Pharmacopoeial monographs (Ph.Eur. / USP-NF / KP) for excipients and general methods; ICH Quality guidelines (Q1A(R2), Q1B, Q2(R2), Q3A/B/C/D, Q5A(R2), Q5C, Q5E, Q6B, Q7, Q8(R2), Q9(R1), Q11, Q12, Q14); and peptide-CMC and permeation-enhancer literature as cited in Module 3.